Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overall survival. This clinical trial will investigate if a new FDA approved medication called Nivolumab (NIVO) (which is a checkpoint blockade immunotherapy) combined with chemotherapy based on the patients risk status to get the patient into the best response possible. Then patients will receive lower doses of chemoimmunotherapy and allogeneic stem cell transplantation (stem cells from another person). The investigators this this new treat

Trial Details

NCT ID
NCT07013565
Phase
PHASE2
Sponsor
New York Medical College
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Vinblastine (Velban)
  • Brentuximab vedotin (Adcetris)
  • Nivolumab (Opdivo)
Locations (sample)
  • Valhalla, New York, United States|41.07482,-73.77513

Key Eligibility Criteria

  • Patients must weigh ≥10 kilograms at the time of study enrollment.
  • Patients with relapsed or refractory histologically or cytologically proven ALK-positive anaplastic large cell lymphoma meeting Low or High Risk Cr…
  • Low Risk Cohort (LR cohort):
  • Any patient with FIRST RELAPSE \> ONE YEAR from initial diagnosis of de novo ALK+ ALCL,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →